Results 1 to 10 of about 35,120,764 (296)

Regulation of the programmed cell death protein 1/programmed cell death ligand 1 axis in relapsing–remitting multiple sclerosis [PDF]

Brain Communications, 2023
Abstract The programmed cell death protein 1/programmed cell death ligand 1 axis plays an important role in the adaptive immune system and has influence on neoplastic and inflammatory diseases, while its role in multiple sclerosis is unclear.
Thanos Tsaktanis, Mathias Linnerbauer, Lena Lößlein, Daniel Farrenkopf, Oliver Vandrey, Anne Peter, Ana Cirac, Tobias Beyer, Lucy Nirschl, Verena Grummel, Mark Mühlau, Matthias Bussas, Bernhard Hemmer, Francisco J Quintana, Veit Rothhammer   +14 more
openaire   +5 more sources

Protective effects of blocking PD-1 pathway on retinal ganglion cells in a mouse model of chronic ocular hypertension

Frontiers in Immunology, 2023
PurposeIn this study, we aimed to investigate whether Programmed cell death 1 ligand 1/programmed cell death 1 ligand 2 (PD-L1/PD-L2) double knockout (dKO) has a protective effect on RGCs in a mouse model of chronic ocular hypertension (COHT).MethodsWe ...
Siqi Sheng, Siqi Sheng, Siqi Sheng, Siqi Sheng, Yixian Ma, Yixian Ma, Yixian Ma, Yixian Ma, Yue Zou, Yue Zou, Yue Zou, Yue Zou, Fangyuan Hu, Fangyuan Hu, Fangyuan Hu, Fangyuan Hu, Ling Chen, Ling Chen, Ling Chen, Ling Chen   +19 more
doaj   +1 more source

Efficacy of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: A systematic review and meta-analysis

Tzu Chi Medical Journal, 2023
Objectives: This study aimed to investigate the efficacy and safety of programmed cell death-1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors in patients with advanced hepatocellular carcinoma (HCC).
Tzu-Rong Peng, Li-Jou Yang, Ta-Wei Wu
doaj   +1 more source

D-1 / PD-L1 EXPRESSION IN INVASIVE BREAST CARCINOMA / CANCER

Pakistan Armed Forces Medical Journal, 2021
Objective: To investigate the immunohistochemical expression of PD-1 and PD-L1 in breast cancer cases and its correlation with clinicopathological factors. Study Design: Cross sectional study. Place and Duration of Study: Histopathology department,
Sammeen Salim, Muhammad Asif, Rabia Ahmed, Muhammad Tahir Khadim   +3 more
doaj   +1 more source

Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer

Therapeutic Advances in Medical Oncology, 2020
Background: The introduction of antibodies targeting programmed cell death protein 1 (PD-1) and programmed cell death-ligand 1 (PD-L1) into clinical practice has had a revolutionary effect on cancer treatment.
Bin Zhao, Hong Zhao, Jiaxin Zhao
doaj   +1 more source

Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors

Cancer Biology & Medicine, 2020
The programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) signaling pathway is an important mechanism in tumor immune escape, and expression of PD-L1 on tumor cells has been reported more frequently.
Min Liu, Qian Sun, Feng Wei, Xiubao Ren
doaj   +1 more source

Comparison of Immune Checkpoint Molecules PD-1 and PD-L1 in Paired Primary and Recurrent Glioma: Increasing Trend When Recurrence

Brain Sciences, 2022
Purpose: This study aims to investigate PD-1/PD-L1 expression patterns in paired primary and recurrent gliomas. Methods: From January 2008 to December 2014, 42 patients who underwent surgical resections of primary and recurrent gliomas were ...
Wei Yu, Anwen Shao, Xiaoqiu Ren, Zexin Chen, Jinghong Xu, Qichun Wei   +5 more
doaj   +1 more source

Analysis of the Correlation between Molecular Structural Differences of PD-1/PD-L1 Inhibitors and Adverse Events

Chinese Journal of Lung Cancer, 2020
As a new method, immunotherapy which is targeting programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) plays a more and more important role in the treatment of malignant tumors.
Tongji XIE, Shouzheng WANG, Puyuan XING
doaj   +1 more source

Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1 [PDF]

JAMA Oncology, 2019
Therapies to inhibit programmed cell death 1 and its ligand (anti-PD-1/PD-L1) provide significant survival benefits in many cancers, but the efficacy of these treatments varies considerably across different cancer types. Identifying the underlying variables associated with this cancer type-specific response remains an important open research challenge ...
Joo Sang, Lee, Eytan, Ruppin
openaire   +2 more sources

Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma

Chinese Journal of Cancer, 2017
Background Anti-programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) immunotherapy has been proved to be effective on gastric cancer in ongoing clinical trials.
Yuan Gao, Su Li, Dazhi Xu, Shangxiang Chen, Yuchen Cai, Wenqi Jiang, Xinke Zhang, Jin Sun, Kefeng Wang, Boyang Chang, Fenghua Wang, Minghuang Hong   +11 more
doaj   +1 more source